Announcements Trials
Browse Landscape

Phase

Phase 2 90Phase 3 52Phase 1 30Phase 1/2 12Phase 2/3 2Phase EARLY_PHASE1 1Phase 4 1

Status

Recruiting 2

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 1Genitourinary 1

Conditions

Renal Pelvis and Ureter Urothelial Carcinoma 1Endometrial Neoplasms 1

Interventions

Cisplatin 22Magnetic Resonance Spectroscopy 18Gemcitabine 14Carboplatin 14pembrolizumab 13Specimen Handling 13Paclitaxel 13Bevacizumab 11Radiotherapy 10Nivolumab 10atezolizumab 8Radiation 8Platinum 8Doxorubicin 8Docetaxel 81,2-diaminocyclohexaneplatinum II citrate 8Pemetrexed 7Drug Therapy 7Dexamethasone 7Temozolomide 6Ipilimumab 6Surgical Procedures, Operative 5Rituximab 5Radiotherapy, Intensity-Modulated 5Prednisone 5Cytarabine 5Cyclophosphamide 5Biopsy 5130-nm albumin-bound paclitaxel 5venetoclax 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2/3 × durvalumab × 90 days × Clear all
NCT05255653 2026-05-15

RAINBO

Leiden University Medical Center

Phase 2/3 Recruiting
1,615 enrolled
Gynecologic

Endometrial Neoplasms

NCT04628767 2026-05-13

Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer

National Cancer Institute (NCI)

Phase 2/3 Recruiting
249 enrolled
Genitourinary

Renal Pelvis and Ureter Urothelial Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡